CCRM’s focus on strong technical collaboration, project management and transparency has allowed us to build robust long-term relationships with leading cell and gene therapy companies.
CCRM prides itself on taking a client-centric approach to its various service offerings, adding value and expertise in a tailored manner that best aligns with clients’ expectations and regulatory requirements.

Our approach has three core elements

ASSESS

Our technical experts listen to your specific needs and design a comprehensive development and manufacturing plan.

COLLABORATE

CCRM is an extension of your team, working with you to identify the process pain points, tools and technologies for your program.

EXECUTE

Our team has a strong track record of tackling complex projects, on-time and on-budget. We are staffed by 135+ employees who have helped to support three IND filings since 2019, with more to come.

  • ASSESS: From the very first conversations with our business development team and technical subject matter experts, we listen actively to understand our clients’ specific needs. Then we design an iterative and transparent development and manufacturing plan.
  • COLLABORATE: CCRM is an extension of our clients’ teams, working with them to identify gaps in the process, equipment, reagents and technologies, and proposing vendor-agnostic recommendations to best enable their process and product for the next stage of development. Throughout the project, clients have routine interactions with our technical leaders. Further, given the co-location of our process development and Good Manufacturing Practices compliant operations, our manufacturing science and technology (MSAT) staff is involved early on in projects to observe first-hand how complex process manipulations will need to be managed when the process is ready for engineering and GMP batches.
  • EXECUTE: A strong project management office, coupled with a phase-appropriate quality approach, allows our teams to execute effectively across a range of complex projects, within client timeline and budget expectations. Another key element of success is to have clearly identified stakeholders and a well-defined escalation pathway to resolve challenges in an expeditious and collaborative manner. This focus on execution has allowed us to support three Investigational New Drug (IND) filings since 2019, with more to come as our clients advance their programs.

Learn more about our approach

Customer Testimonials

We’ve found an ongoing partner [in CCRM] – Dr. Ralph Brandenberger, SVP Technical Operations, Nkarta

[The team] really helped us get to where we are today. – Dr. Lara Ionescu Silverman, PhD, Senior Director, Research and Development, DiscGenics

It almost felt like they [CCRM] were an extension of our team. The culture and adaptive nature, flexibility and communication were excellent. – Edel O’Toole, Senior Director Project & Vendor Management, Avectas

Read our latest blog posts